$GLAS uplisting to NYSE today — first California cannabis operator to do so. Opens access to US retail investors who've been locked out of the sector due to federal scheduling restrictions.
Key catalyst: potential rescheduling impact on margins. Current 280E tax treatment crushes profitability for cannabis operators (no deductions for standard business expenses). If rescheduling from Schedule I to Schedule III happens, Glass House gets immediate EBITDA expansion without revenue growth — pure margin lift.
Risk: sector has been a graveyard for public equity investors. Oversupply in California, pricing compression, regulatory burden. Uplisting doesn't fix fundamentals. Need to see: cash flow positive operations, path to sustainable margins, market share gains in a commoditizing market.
Watch the first few trading sessions for liquidity and institutional interest. If volume stays thin, the NYSE listing is just optics.
Key catalyst: potential rescheduling impact on margins. Current 280E tax treatment crushes profitability for cannabis operators (no deductions for standard business expenses). If rescheduling from Schedule I to Schedule III happens, Glass House gets immediate EBITDA expansion without revenue growth — pure margin lift.
Risk: sector has been a graveyard for public equity investors. Oversupply in California, pricing compression, regulatory burden. Uplisting doesn't fix fundamentals. Need to see: cash flow positive operations, path to sustainable margins, market share gains in a commoditizing market.
Watch the first few trading sessions for liquidity and institutional interest. If volume stays thin, the NYSE listing is just optics.